An Autopsy Case of Fulminant Hepatitis in a Patient with Multiple Sclerosis Treated by Interferon-Beta-1a

A 44-year-old woman with multiple sclerosis (MS) receiving interferon (IFN)-beta-1a treatment was admitted to a local hospital for severe icterus and liver injury. She was transferred to our university hospital because fulminant hepatitis (FH) was suspected. She was diagnosed with acute-type FH based on hepatic coma, severe liver injury and liver failure, and she received plasma exchange and continuous hemodiafiltration therapy. On hospital day 6, she died from liver failure despite intensive care. An autopsy revealed histological findings consistent with FH. Physicians should monitor the hepatic function of MS patients receiving IFN-beta-1a treatment, as serious events can occur in rare cases.

[1]  M. Pawłowska,et al.  Acute liver failure and liver transplantation in a patient with multiple sclerosis treated with interferon beta. , 2015, Neurologia i neurochirurgia polska.

[2]  A. Gadano,et al.  Interferon beta 1a-induced severe autoimmune hepatitis in patients with multiple sclerosis: report of two cases and review of the literature. , 2015, Annals of hepatology.

[3]  A. Cross,et al.  Established and novel disease‐modifying treatments in multiple sclerosis , 2014, Journal of internal medicine.

[4]  Jiezhun Gu,et al.  Presentation and Outcomes with Clinically Apparent Interferon Beta Hepatotoxicity , 2013, Digestive Diseases and Sciences.

[5]  H. Takikawa.  Recent status of drug‐induced liver injury , 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

[6]  G. Pietrosi,et al.  Fulminant hepatic failure and autoimmune disorders in patient with multiple sclerosis on interferon beta 1a: a fatal combination? , 2008, Transplant international : official journal of the European Society for Organ Transplantation.

[7]  P. Vermersch,et al.  Autoimmune hepatitis and multiple sclerosis: a coincidental association? , 2005, Multiple sclerosis.

[8]  L. Murri,et al.  Long-term follow-up of 106 multiple sclerosis patients undergoing interferon-beta 1a or 1b therapy: predictive factors of thyroid disease development and duration. , 2005, The Journal of clinical endocrinology and metabolism.

[9]  D. Miller,et al.  Interferon β-1a in primary progressive MS , 2003, Neurology.

[10]  J. Oger,et al.  Fulminant liver failure during interferon beta treatment of multiple sclerosis , 2001, Neurology.

[11]  M. Manns,et al.  International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. , 1999, Journal of hepatology.

[12]  G. Francis,et al.  Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. , 2003, Drug safety.

[13]  D. Chard,et al.  Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. , 2003, Neurology.

[14]  G. Francis,et al.  Hepatic Reactions During Treatment of Multiple Sclerosis with Interferon-β-1a , 2003 .